This company has been marked as potentially delisted and may not be actively trading. NASDAQ:RARX Ra Pharmaceuticals (RARX) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Ra Pharmaceuticals Stock (NASDAQ:RARX) 30 days 90 days 365 days Advanced Chart Get Ra Pharmaceuticals alerts:Sign Up Key Stats Today's Range$47.99▼$47.9950-Day Range$47.99▼$48.0052-Week Range$19.64▼$48.02Volume30,200 shsAverage Volume1.16 million shsMarket Capitalization$2.27 billionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Ra Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system. The company's peptide chemistry platform enables the production of synthetic macrocyclic peptides that combine the diversity and specificity of antibodies with the pharmacological properties of small molecules. Its lead product candidate is Zilucoplan, an injection into the tissue under the skin that has completed Phase II clinical trial for the treatment of generalized myasthenia gravis (gMG); has completed Phase II clinical trial for treating paroxysmal nocturnal hemoglobinuria (PNH); and has completed Phase Ib clinical trial to treat patients with renal impairment. The company's pre-clinical programs include Factor D inhibition for treating C3 glomerulonephritis and dense deposit disease; and inhibitors of other complement factors for renal, autoimmune, and central nervous system diseases. It has collaboration and license agreement with Merck & Co., Inc. to identify orally available cyclic peptides for non-complement program targets, and provide research and development services. Ra Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Cambridge, Massachusetts. Read More Receive RARX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ra Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address RARX Stock News HeadlinesDeepCure links with Leeds Institute to bring AI-based RA drug to clinicAugust 20, 2024 | msn.comRA: Discount Continues To Leave Some OpportunityJanuary 23, 2024 | seekingalpha.comA new rule goes live in July — and the banks are quietly cashing inA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Street and the Big Banks… It gives them the green light to treat a certain tangible asset as equivalent to cold, hard cash. Not stocks. Not real estate. And definitely not the U.S. dollar. We're talking about something they don't want you to notice — because the fewer people who act on this, the better it is for them. | American Alternative (Ad)Imperial Petroleum, ARS Pharmaceuticals Stock, and More See Action From Activist InvestorsSeptember 8, 2023 | barrons.comAnthera Pharmaceuticals (ANTH) Stock Dropping After Pricing Public OfferingMay 29, 2023 | thestreet.comUPDATE 1-AstraZeneca to buy U.S.-based CinCor Pharma in $1.8 bln dealJanuary 10, 2023 | msn.comRA Capital Closes Position in Astria Therapeutics (ATXS)November 15, 2022 | 247wallst.comRARX_old Historical DataAugust 20, 2022 | investing.comSee More Headlines RARX Stock Analysis - Frequently Asked Questions How were Ra Pharmaceuticals' earnings last quarter? Ra Pharmaceuticals Inc (NASDAQ:RARX) issued its quarterly earnings results on Thursday, February, 27th. The company reported ($0.79) EPS for the quarter, missing the consensus estimate of ($0.63) by $0.16. When did Ra Pharmaceuticals IPO? Ra Pharmaceuticals (RARX) raised $75 million in an initial public offering on Wednesday, October 26th 2016. The company issued 5,800,000 shares at a price of $12.00-$14.00 per share. Credit Suisse, Jefferies and BMO Capital Markets served as the underwriters for the IPO and SunTrust Robinson Humphrey was co-manager. What other stocks do shareholders of Ra Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Ra Pharmaceuticals investors own include Corbus Pharmaceuticals (CRBP), Viking Therapeutics (VKTX), Gilead Sciences (GILD), Verastem (VSTM), Amarin (AMRN), Bausch Health Cos (BHC) and Galmed Pharmaceuticals (GLMD). Company Calendar Last Earnings2/27/2020Today7/06/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:RARX CIK1481512 Webwww.rapharma.com Phone617-401-4060FaxN/AEmployees72Year FoundedN/AProfitability EPS (Trailing Twelve Months)($2.31) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$102.69 million Net MarginsN/A Pretax MarginN/A Return on Equity-44.61% Return on Assets-41.60% Debt Debt-to-Equity Ratio0.01 Current Ratio14.78 Quick Ratio14.79 Sales & Book Value Annual Sales$3 million Price / Sales757.11 Cash FlowN/A Price / Cash FlowN/A Book Value$5.56 per share Price / Book8.63Miscellaneous Outstanding Shares47,329,000Free FloatN/AMarket Cap$2.27 billion OptionableOptionable Beta1.05 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (NASDAQ:RARX) was last updated on 7/7/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ra Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Ra Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.